Overview DP-R213 Phase 1 Pharmacokinetics Study Status: Completed Trial end date: 2017-03-29 Target enrollment: Participant gender: Summary A randomized, open-label, crossover, Phase I clinical trial to compare the pharmacokinetics of DP-R213 (Raloxifenel and Cholecaliferol fixed dose combinations) in comparison to each component administered alone in healthy male volunteers. Phase: Phase 1 Details Lead Sponsor: Alvogen KoreaTreatments: CholecalciferolRaloxifene Hydrochloride